retatrutide efficacy clinical trials A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Clinical trials of subcutaneous tirzepatide,

Nothing severe but definitely noticeable

Industry analysts expect a potential approval window around 2026 to 2027, pending trial results and regulatory review

Safety and Side Effect Profile Both compounds belong to the same general drug class and share a broadly similar side effect profile, largely gastrointestinal in nature

The most common side effects of GLP-1 drugs are gastrointestinal and mild, particularly when starting treatment

Table of Contents: What are GLP-1 medications

Its expansion into NASH, CVD, neurodegenerative diseases, and obesity-related cancers could redefine chronic disease management, offering a single therapy with multifaceted benefits